Novavax Gains as Ebola Vaccine Shows Human Immune Response
Electron Micrograph of the Ebola virus.
Photograph: BSIP/UIG via Getty ImagesThis article is for subscribers only.
Novavax Inc.’s Ebola vaccine helped healthy people develop an immune response against the deadly virus in an early trial. The shares rose.
In a randomized study compared against a placebo, the vaccine pushed participants’ immune systems to build up antibodies to fight Ebola when combined with a supplement to boost production of the proteins, according to Greg Glenn, Novavax’s head of research.